Am J Transplant, Volume 19, Suppl 3 Archives - Page 108 of 214 - ATC Abstracts

2019 American Transplant Congress
The Molecular Features of Chronic Lung Allograft Dysfunction (CLAD) in Transbronchial and Endobronchial Mucosa Biopsies
M. D. Parkes¹, K. M. Halloran¹, J. Chang², P. F. Halloran and the INTERLUNG study group¹
¹University of Alberta, Edmonton, AB, Canada, ²ATAGC, University of Alberta, Edmonton, AB, Canada
*Purpose: Chronic lung allograft dysfunction (CLAD), the major long-term problem in lung transplantation, requires new strategies for prevention and management. However, CLAD is infrequently diagnosed…
2019 American Transplant Congress
Robotic Kidney Transplantation For Obese Patients: First Year Experience In Single Institute
S. Lee¹, L. A. Cantrell², A. Agarwal¹, S. K. Rasmussen¹, S. Pelletier¹, K. Brayman¹, J. Oberholzer¹
¹Division of Transplant Surgery, Department of Surgery, University of Virginia Health Sciences Center, Charlottesville, VA, ²Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia Health Sciences Center, Charlottesville, VA
*Purpose: Obesity with end-stage renal disease significantly impacts intraoperative and postoperative complications in kidney transplantation. Robot-assist procedures have been an attractive modality to overcome barriers…
2019 American Transplant Congress
Endovascular Repair Of Abdominal Aortic Aneurysms In Kidney Transplant Recipients
S. Kwon¹, D. Jung¹, Y. Kim¹, S. Park², S. Yoon²
¹Department of Vascular and Transplant Surgery, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of, ²Department of Vascular and Transplant Surgery, The Catholic Universtiy of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of
*Purpose: The possibility to diagnosis abdominal aortic aneurysm (AAA) in patients who underwent kidney transplantation (KT) is increasing. Immunosuppressive agents may effect on AAA progression.…
2019 American Transplant Congress
Mortality around the One-Year Survival Metric after Liver Transplantation in the United States
C. Blebea¹, P. Chatterjee², A. Nathan¹, J. Diamond¹, H. J. Goldberg², A. Courtwright¹
¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²Brigham and Women’s Hospital, Boston, MA
*Purpose: Liver transplant programs in the United States are evaluated on one-year survival, among other factors. This may create an unintended incentive to continue life-sustaining…
2019 American Transplant Congress
Early Readmission After Renal Transplant As A Valuable Quality Measure
S. Kim¹, A. Osband¹, B. Merhi², G. Bayliss², R. Gohh², P. Morrissey¹
¹Surgery, Rhode Island Hospital, Providence, RI, ²Nephrology, Rhode Island Hospital, Providence, RI
*Purpose: Patient and graft survival have been criticized as imprecise measures of transplant program quality. Thirty-day (30d) readmission rates, available nationally and attainable locally, may…
2019 American Transplant Congress
Daratumumab for Treatment of Antibody-Mediated Rejection in a Kidney Transplant Recipient
S. C. Jordan¹, R. Vescio², M. Toyoda³, N. Ammerman¹, E. Huang¹, A. Peng¹, S. Sethi¹, R. Najjar¹, K. Lim¹, A. Vo¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Ctr, Los Angeles, CA, ²Cedars-Sinai Medical Ctr, Los Angeles, CA, ³Transplant Immunology Lab, Cedars-Sinai Medical Ctr, Los Angeles, CA
*Purpose: Antibody-Mediated Rejection (ABMR) is a severe form of rejection mediated by B-cells, plasma cells and antibodies. The consequences to the patients with ABMR are…
2019 American Transplant Congress
Induction Therapy Modulated by the Absence of Preformed Donor-Specific Antibodies (DSAS) Regardless of the Level of Sensitization
M. Cristelli, K. Linhares, R. de Marco, L. Viana, C. Felipe, M. Gaspar, C. Peixoto, G. Marcelo Gomes, J. Toniato Rezende, K. Nunes Ficher, L. Alfaro Villanueva, V. Lima, M. Gerbase de Lima, J. Medina Pestana, H. Tedesco Silva Junior
Núcleo de Ensino e Pesquisa, Hospital do Rim, São Paulo, Brazil
*Purpose: We hypothesized that sensitized patients with preformed DSAs other than anti-HLA A, B, DR could receive less intensive induction therapy.*Methods: Single center retrospective cohort…
2019 American Transplant Congress
Immunologic Impact Of Native Kidney Function On Liver Transplant Patients
M. Mujtaba, S. Merwat, J. Fair, M. Bilal, A. Chatila, R. Kulkarni, J. Zou, S. Hussain, A. Gamilla-Crudo
Univ. of Texas Medical Branch, Galveston, TX
*Purpose: Renal failure in the setting of liver transplantation (LTx) is common and has an adverse impact on short and long-term graft and patient survival.…
2019 American Transplant Congress
Peripheral Blood Regulatory T Cells In The Folow In The Kidney-transplant Patients
M. A. Carmona-Escamilla¹, G. Queipo², L. A. Garcia-Mosqueda³, R. Lascurain⁴
¹Nephrology, Pemex, CDMX, Mexico, ²Genetics, Hospital General, CDMX, Mexico, ³UNAM, CDMX, Mexico, ⁴Inmunologia, UNAM, CDMX, Mexico
*Purpose: Investigate the peripheral blood levels of CD4+CD25+FOXP3p3+ regulatory T cells (Tregs) in patients with kidney transplant at least one year after kidney transplantation and…
2019 American Transplant Congress
In Vivo Treg Expansion under Costimulation Blockade Targets Early Rejection and Improves Long-Term Outcome
C. Schwarz¹, B. Mahr², L. Unger¹, N. Pilat², H. Regele³, T. Wekerle²
¹Dept. of Surg. / Div. of Transplantation, Medical University Vienna, Vienna, Austria, ²Dept. of Surg. / Section of Transplantation Immunology, Medical University Vienna, Vienna, Austria, ³Clinical Institute of Pathology, Medical University Vienna, Vienna, Austria
*Purpose: Early rejection episodes are a major problem under CTLA4Ig/belatacept-based immunosuppression. We have previously shown that CTLA4Ig therapy is dependent on Tregs at low (LD)…